Zepbound, the new GLP-1 weight-loss drug from Eli Lilly & Co., has been approved by the Food and Drug Administration for ...

The FDA on Friday approved Eli Lilly's weight-loss drug Zepbound as a treatment for moderate-to-severe sleep apnea and ...

The FDA said studies have shown that by aiding weight loss, Zepbound improves sleep apnea symptoms in some patients.

The agency’s decision expands the use of Zepbound and could potentially pave the way for Eli Lilly to gain broader insurance ...

Key Takeaways Eli Lilly's Zepbound has been approved by the Food and Drug Administration (FDA) as a treatment for adults with ...

Consumers who take copies of the weight loss drug Zepbound and diabetes drug Mounjaro will need to find a new source for ...

The US Food and Drug Administration on Friday approved the first prescription medicine for obstructive sleep apnea: the ...

The Food and Drug Administration expanded the approval of weight loss drug Zepbound to treat obstructive sleep apnea in ...

With more people taking the weight-loss drugs Wegovy and Zepbound, one question inevitably ... In March, the U.S. Food and Drug Administration allowed the company to add on Wegovy's label that ...

On Thursday, the Food and Drug Administration said Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro to treat diabetes, is no longer in short supply. The FDA allows ...

the weight-loss drug Zepbound. The medicine, part of the class known as GLP-1 receptor agonists that also includes Ozempic, was cleared to treat moderate to severe forms of the sleep condition in ...